Literatuur
Dagan R, Bar-David Y. Double-blind study comparing erythromycin and mupirocin for treatment of impetigo in children: implications of a high prevalence of erythromycin-resistant Staphylococcus aureus strains. Antimicrob Agents Chemother 1992;36:287-90.
Bruijnzeels MA, Van Suijlekom-Smit LWA, Van der Velden J, Van der Wouden JC. The child in general practice. Rotterdam/Utrecht: Erasmus Universiteit/NIVEL, 1993.
Boukes FS, Van der Burgh JJ, Nijman FC, Sampers GMHA, Simon B, Romeijnders ACM, et al. NHG-Standaard Bacteriële Huidinfecties. Huisarts Wet 1999;41:427-37.
Resnick DS. Staphylococcal and streptococcal skin infections: pyodermas and toxin-mediated syndromes. In: Harper J, Oranje A, Prose N, editors. Textbook of Pediatric Dermatology. 1st ed. Oxford: Blackwell, 2000:369-72.
Hay RJ, Adriaans BM. Bacterial infections. In: Champion RH, Burton JL, Ebling FJG, editors. Rook/Wilkinson/Ebling, Textbook of Dermatology. 6th ed. Oxford: Blackwell, 1998: 1109-11.
Carruthers R. Prescribing antibiotics for impetigo. Drugs 1988;36:364-9.
Baltimore RS. Treatment of impetigo: a review. Pediatr Infect Dis 1985;4:597-601.
Espersen F. Resistance to antibiotics used in dermatological practice. Br J Dermatol 1998;139:4-8.
Mertz PM, Marshall DA, Eaglstein WH, Piovanetti Y, Montalvo J. Topical mupirocin treatment of impetigo is equal to oral erythromycin therapy. Arch Dermatol 1989;125:1069-73.
De Neeling AJ, Van Leeuwen WJ, Schouls LM, Schot CS, Van Veen-Rutgers A, Beunders AJ, et al. Resistance of staphylococci in the Netherlands: surveillance by an electronic network during 1989-1995. J Antimicrob Chemother 1998;41:93-101.
Rogers M, Dorman DC, Gapes M, Ly J. A three-year study of impetigo in Sydney. Med J Aust 1987;147:63-5.
Bass JW, Chan DS, Creamer KM, Thompson MW, Malone FJ, Becker TM, et al. Comparison of oral cephalexin, topical mupirocin, and topical bacitracin for treatment of impetigo. Pediatr Inf Dis J 1997;16:708-9.
Britton JW, Fajardo JE, Krafte-Jacobs B. Comparison of mupirocin and erythromycion in the treatment of impetigo. J Pediatr 1990;117:827-9.
Godtfredsen WO, Roholt K, Tybring L. Fucidin: a new orally active antibiotic. Lancet 1962;i:928-31.
Gilbert M. Topical 2% mupirocin versus 2% fusidic acid ointment in the treatment of primary and secondary skin infections. J Am Acad Dermatol 1989;20:1083-7.
Morley PAR, Munot LD. A comparison of sodium fusidate ointment and mupirocin ointment in superficial skin sepsis. Curr Med Res Opin 1988;11:142-8.
Van Amstel L, Koning S, Van Suijlekom-Smit LWA, Oranje AP, Van der Wouden JC. De behandeling van impetigo contagiosa, een systematisch overzicht. Huisarts Wet 2000;43:247-52.
Clinical Microbiology Procedures Handbook. Washington (DC): American Society for Microbiology, 1992.
NCCLS. Performance Standards for antimicrobial disk susceptibility tests – seventh edition; Approved standard; M2-A7, vol. 20 no.1, 2000.
NCCLS. Performance Standards for antimicrobial disk susceptibility testing; eleventh informational supplement; M100 B S11, vol 21 no.1, 2001.
Ruby RJ, Nelson JD. The influence of hexachlorophene scrubs on the response to placebo or penicillin therapy in impetigo. Pediatrics 1973;52:854-9.
Dajani AS, Hill PL, Wannamaker LW. Experimental infection of the skin in the hamster simulating human impetigo: II. Assessment of various therapeutic regimens. Pediatrics 1971:48;83-90.
Editor information
Rights and permissions
Copyright information
© 2008 Bohn Stafleu van Loghum, onderdeel van Springer Uitgeverij
About this chapter
Cite this chapter
Koning, S. et al. (2008). Fusidinezuurcrème ter behandeling van impetigo: een dubbelblind gerandomiseerd placebogecontroleerd onderzoek. In: van Weert, H. (eds) Schatjes zijn het. Huisarts en Wetenschap. Bohn Stafleu van Loghum, Houten. https://doi.org/10.1007/978-90-313-6642-2_11
Download citation
DOI: https://doi.org/10.1007/978-90-313-6642-2_11
Publisher Name: Bohn Stafleu van Loghum, Houten
Print ISBN: 978-90-313-5342-2
Online ISBN: 978-90-313-6642-2
eBook Packages: Dutch language eBook collection